Detalhe da pesquisa
1.
Systemic amyloidosis from A (AA) to T (ATTR): a review.
J Intern Med
; 289(3): 268-292, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32929754
2.
Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis.
J Intern Med
; 281(6): 611-619, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28439924
3.
Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT.
Bone Marrow Transplant
; 41(12): 1013-9, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18332915
4.
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.
Leukemia
; 21(9): 2035-42, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17581613
5.
Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation.
Bone Marrow Transplant
; 53(2): 155-161, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29131152
6.
Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation.
Leukemia
; 32(3): 712-718, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28848227
7.
Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.
Leukemia
; 32(3): 729-735, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28919633
8.
Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial.
Leukemia
; 32(3): 719-728, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28860655
9.
Natural history of t(11;14) multiple myeloma.
Leukemia
; 32(1): 131-138, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28655925
10.
The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents.
Bone Marrow Transplant
; 52(1): 34-40, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27548464
11.
Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival.
Leukemia
; 31(1): 92-99, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27211265
12.
Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival.
Bone Marrow Transplant
; 52(8): 1126-1132, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28394369
13.
Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma.
Blood Cancer J
; 7(9): e600, 2017 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28862698
14.
Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma.
Blood Cancer J
; 7(2): e528, 2017 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-28211889
15.
Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression.
Leukemia
; 31(1): 130-135, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27457702
16.
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category.
Leukemia
; 31(7): 1562-1569, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27904139
17.
Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma.
Bone Marrow Transplant
; 37(11): 1017-22, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16633361
18.
Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era.
Blood Cancer J
; 6(12): e512, 2016 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27983726
19.
Autologous stem cell transplant for multiple myeloma patients 70 years or older.
Bone Marrow Transplant
; 51(11): 1449-1455, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27376447
20.
Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.
Leukemia
; 30(3): 633-9, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26487275